3 clinical compounds licensed from Sanofi kick start the development of the company.
Read more about Ixaltis in the medias and check our press releases.
0
molecules from Sanofi (exclusive worldwide license)
0
creation of the biotech start-up
0
first phase II clinical study with Litoxetine
0
centers in six countries for this study
0
female subjects aged 18 to 75
